미국의 종양 정보 시스템 시장 규모, 점유율, 동향 분석 보고서 : 제품과 서비스별, 용도별, 최종 용도별, 부문별 예측(2025-2033년)

Market Size & Trends:

The U.S. oncology information systems market size was estimated at USD 900.29 million in 2024 and is projected to grow at a CAGR of 7.56% from 2025 to 2033. The growing prevalence of cancer among various demographics and the rising demand for advanced innovative oncology information systems (OIS) are some of the driving factors for the U.S. market. Oncology information solutions deployment is high in hospitals & cancer research institutes in the U.S. due to the rise in the prevalence of cancer and the increase in healthcare expenditure budget.

The U.S. oncology information system (OIS) market is poised for significant growth, driven by the rising cancer burden and the increasing integration of advanced healthcare IT solutions. According to the National Cancer Institute, over 2 million new cancer cases are projected to be diagnosed in the U.S. in 2024, with an estimated 611,720 cancer-related deaths. This escalating disease incidence necessitates robust data management and clinical decision support systems, thereby accelerating the demand for OIS platforms across healthcare facilities.

Moreover, the healthcare sector in the U.S. has witnessed a surge in the adoption of digital technologies aimed at optimizing workflows, administrative functions, and patient care delivery. Oncology information systems, equipped with advanced functionalities such as treatment planning, data visualization, and patient tracking, have emerged as critical tools for improving clinical outcomes and operational efficiency.

Furthermore, increased investment in oncology R&D, supported by both public and private organizations, is fostering product innovation. For instance, the American Brachytherapy Society (ABS), a prominent nonprofit founded in 1978, actively supports the advancement of brachytherapy through professional education, research promotion, and awareness-building initiatives. Such organizations play a pivotal role in driving innovation and knowledge dissemination in oncology care.

The growing integration of artificial intelligence (AI) into oncology workflows is expected to further propel the expansion of the U.S. oncology information systems industry. In October 2024, Ontada, a McKesson Corporation subsidiary, partnered with Microsoft to utilize Azure AI, including Azure OpenAI Service, to enhance the processing of unstructured oncology data. This collaboration aims to extract actionable insights from complex clinical documents, ultimately supporting data-driven treatment planning and real-time decision-making.

These factors, such as rising cancer prevalence, expanding healthcare IT adoption, increased R&D activities, and AI-driven innovation, are collectively expected to drive sustained growth of the U.S. oncology information system market over the forecast period.

U.S. Oncology Information Systems Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. oncology information systems market report based on product & service, application, and end use:

• Product & Service Outlook (Revenue, USD Million, 2021 - 2033)
• Software
  • Patient Information Systems
  • Treatment Planning Systems
• Professional Services
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Medical Oncology
• Radiation Oncology
• Surgical Oncology
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals & Diagnostic Imaging Centers
• Ablation Care Centers and Cancer Care Centers
• Government Institutions
• Research Facilities

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Market Definitions
  • 1.2.1. Product & Service Segment
  • 1.2.2. Application Segment
  • 1.2.3. End Use
• 1.3. Information analysis
  • 1.3.1. Market formulation & data visualization
• 1.4. Data validation & publishing
• 1.5. Information Procurement
  • 1.5.1. Primary Research
• 1.6. Information or Data Analysis
• 1.7. Market Formulation & Validation
• 1.8. Market Model
• 1.9. Total Market: CAGR Calculation
• 1.10. Objectives
  • 1.10.1. Objective 1
  • 1.10.2. Objective 2

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Insights Landscape

Chapter 3. U.S. Oncology Information Systems Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
  • 3.2.2. Market restraint analysis
  • 3.2.3. Market opportunity analysis
  • 3.2.4. Market challenges analysis
• 3.3. U.S. Oncology Information Systems Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
    • 3.3.2.4. Environmental Landscape
    • 3.3.2.5. Legal Landscape
    • 3.3.2.6. Social Landscape

Chapter 4. U.S. Oncology Information Systems Market: Product & Service Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. U.S. Oncology Information Systems Market Product & Service Movement Analysis
• 4.3. U.S. Oncology Information Systems Market Size & Trend Analysis, by Product & Service, 2021 to 2033 (USD Million)
• 4.4. Software
  • 4.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.4.2. Patient Information Systems
    • 4.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.4.3. Treatment Planning Systems
    • 4.4.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
• 4.5. Professional Services
  • 4.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. U.S. Oncology Information Systems Market: Application Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. U.S. Oncology Information Systems Market Application Movement Analysis
• 5.3. U.S. Oncology Information Systems Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
• 5.4. Medical Oncology
  • 5.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
• 5.5. Radiation Oncology
  • 5.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
• 5.6. Surgical Oncology
  • 5.6.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. U.S. Oncology Information Systems Market: End Use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. U.S. Oncology Information Systems Market End Use Movement Analysis
• 6.3. U.S. Oncology Information Systems Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
• 6.4. Hospitals & Diagnostic Imaging
  • 6.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
• 6.5. Ablation Care Centers and Cancer Care Centers
  • 6.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
• 6.6. Government Institutions
  • 6.6.1. Market estimates and forecasts 2021 to 2033 (USD Million)
• 6.7. Research Facilities
  • 6.7.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Company/Competition Categorization
• 7.2. Strategy Mapping
• 7.3. Company Market Position Analysis, 2024
• 7.4. Company Profiles/Listing
  • 7.4.1. Elekta AB
    • 7.4.1.1. Company overview
    • 7.4.1.2. Financial performance
    • 7.4.1.3. Product benchmarking
    • 7.4.1.4. Strategic initiatives
  • 7.4.2. Accuray Incorporated
    • 7.4.2.1. Company overview
    • 7.4.2.2. Financial performance
    • 7.4.2.3. Product benchmarking
    • 7.4.2.4. Strategic initiatives
  • 7.4.3. Varian Medical Systems (Siemens Healthineers)
    • 7.4.3.1. Company overview
    • 7.4.3.2. Financial performance
    • 7.4.3.3. Product benchmarking
    • 7.4.3.4. Strategic initiatives
  • 7.4.4. RaySearch Laboratories
    • 7.4.4.1. Company overview
    • 7.4.4.2. Financial performance
    • 7.4.4.3. Product benchmarking
    • 7.4.4.4. Strategic initiatives
  • 7.4.5. Oracle Corporation
    • 7.4.5.1. Company overview
    • 7.4.5.2. Financial performance
    • 7.4.5.3. Product benchmarking
    • 7.4.5.4. Strategic initiatives
  • 7.4.6. BrainLab
    • 7.4.6.1. Company overview
    • 7.4.6.2. Financial performance
    • 7.4.6.3. Product benchmarking
    • 7.4.6.4. Strategic initiatives
  • 7.4.7. Philips Healthcare
    • 7.4.7.1. Company overview
    • 7.4.7.2. Financial performance
    • 7.4.7.3. Product benchmarking
    • 7.4.7.4. Strategic initiatives
  • 7.4.8. Prowess, Inc.
    • 7.4.8.1. Company overview
    • 7.4.8.2. Financial performance
    • 7.4.8.3. Product benchmarking
    • 7.4.8.4. Strategic initiatives
  • 7.4.9. DOSIsoft S.A.
    • 7.4.9.1. Company overview
    • 7.4.9.2. Financial performance
    • 7.4.9.3. Product benchmarking
    • 7.4.9.4. Strategic initiatives
  • 7.4.10. ViewRay Inc.
    • 7.4.10.1. Company overview
    • 7.4.10.2. Financial performance
    • 7.4.10.3. Product benchmarking
    • 7.4.10.4. Strategic initiatives
  • 7.4.11. MIM Software
    • 7.4.11.1. Company overview
    • 7.4.11.2. Financial performance
    • 7.4.11.3. Product benchmarking
    • 7.4.11.4. Strategic initiatives
  • 7.4.12. Flatiron
    • 7.4.12.1. Company overview
    • 7.4.12.2. Financial performance
    • 7.4.12.3. Product benchmarking
    • 7.4.12.4. Strategic initiatives